Modulation of P450-dependent ifosfamide pharmacokinetics: A better understanding of drug activation in vivo

British Journal of Cancer

Volumn 77, Issue 11, 1998, Pages 1768-1776

  Brain, E G C ^a   Yu, L J ^a   Gustafsson, K ^a   Drewes, P ^a   Waxman, D J ^a  

^a Boston University   (United States)

Author keywords

Cytochrome P450; Ifosfamide; Neurotoxicity; Pharmacokinetics

Indexed keywords

CHLOROACETALDEHYDE; CYTOCHROME P450; IFOSFAMIDE; PHENOBARBITAL; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG ACTIVATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG INACTIVATION; DRUG METABOLISM; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER MICROSOME; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031779382     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.295     Document Type: Article

References (56)

1. Aeschlimann C, Cerny T and Kupfer A (1996) Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos 24: 1335-1339
2. Alarcon RA (1968) Fluorometric determination of acrolein and related compounds with m-aminophenol. Anal Chem 40: 1704-1708
3. Allen LM and Creaven PJ (1972) Effect of microsomal activation on interaction between isophosphamide and DNA. J Pharm Sci 61: 2009-2011
4. Arlotto MP, Sonderfan AJ, McKinney MM and Parkinson A (1986) Digitoxin metabolism by liver microsomal cytochrome P-450 and UDP-glucuronosyltransferase and its role in the protection of rats from digitoxin toxicity by pregnenolone-16 alpha-carbonitrile. Arch Biochem Biophys 251: 188-197
5. Arlotto MP, Sonderfan AJ, Klaassen CD and Parkinson A (1987) Studies on the pregnenolone-16 alpha-carbonitrile-inducible form of rat liver microsomal cytochrome P-450 and UDP-glucuronosyltransferase. Biochem Pharmacol 36: 3859-3866
6. Boddy AV, Proctor M, Simmonds D, Lind MJ and Idle JR (1995) Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur J Cancer 31A: 69-76
7. Boddy AV, Yule SM, Wyllie R, Price L, Pearson AD and Idle JR (1996) Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother Pharmacol 38: 147-154
8. Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R et al. (1987). Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23: 311-321
9. Brock N (1996) The history of the oxazaphosphorine cytostatics. Cancer 78: 542-547
10. Cabanillas F, Hagemeister FB, Bodey GP and Freireich EJ (1982) IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60: 693-697
11. Cashman JR, Perotti BY, Berkman CE and Lin J (1996) Pharmacokinetics and molecular detoxication. Environ Health Perspect 104(suppl 1): 23-40
12. Chang TK and Waxman DJ (1993) Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard. Cancer Res 53: 2490-2497
13. Chang TKH, Weber GF, Crespi CL and Waxman DJ (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res 53: 5629-5637
14. Chang TKH, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophy 311:437-442
15. Chen L and Waxman DJ (1995) Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Research 55: 581-589
16. Chen L, Waxman DJ, Chen D and Kufe DW (1996) Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 56: 1331-1340
17. Chen L, Yu LJ and Waxman DJ (1997) Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res 57: 4830-4837
18. Collins JM, Grieshaber CK and Chabnrr BA (1990). Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82: 1321-1326
19. Gibaldi M and Perrier D (1982) Pharmacokinetics. Marcel Dekker: New York
20. Goldin A (1982) Ifosphamide in experimental tumor systems. Sem Oncol 9: 14-23
21. Gonzalez FJ, Crespi CL and Gelboin HV (1991) cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutation Res 247: 113-127
22. Goren MP, Wright RK, Pratt CB and Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet 2: 1219-1220
23. Granvil CP, Wang T, Batist G and Wainer IW (1994) Influence of phenobarbital induction on the enantioselective N-dechloroethylation of ifosfamide enantiomers in the rat. Drug Metab Dispos 22: 165-167
24. Guengerich FP (1989) Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol 29: 241-264
25. Halpert JR (1995) Structural basis of selective cytochrome P450 inhibition. Annu Rev Pharmacol Toxicol 35: 29-53
26. Kamen BA, Frenkel E and Colvin OM (1995) Ifosfamide: should the honeymoon be over? (editorial). J Clin Oncol 13: 307-309
27. Kraner JC, Morgan ET, Poet TS, Born SL, Burnett VL and Halpert JR (1996) Suppression of rat hepatic microsomal cytochromes P450 by cyclophosphamide is correlated with plasma thyroid hormone levels and displays differential strain sensitivity. J Pharmacol Exp Ther 276: 258-264
28. Kurowski V and Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33: 36-42
29. LeBlanc GA and Waxman DJ (1990) Mechanisms of cyclophosphamide action on hepatic P-450 expression. Cancer Res 50: 5720-5726
30. LeBlanc GA, Sundseth SS, Weber GF and Waxman DJ (1992) Platinum anticancer drugs modulate P-450 mRNA levels and differentially alter hepatic drug and steroid hormone metabolism in male and female rats. Cancer Res 52: 540-547
31. Levitt M, Warr D, Yelle L, Rayner HL, Lofters WS, Perrault DJ, Wilson KS, Latreille J, Potvin M, Warner E, Pritchard KI, Plamer M, Zee B and Pater JL (1993) Ondansetron compared with dexamethasone and metoclopramide in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. N Engl J Med 328: 1081-1084
32. Lin JH (1995) Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23: 1008-1021
33. Morgan LR, Harrison EF, Hawke JE, Hunter HL, Costanzi JJ, Plotkin D, Tucker WG and Worrall PM (1982) Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. Semin Oncol 9: 66-70
34. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW (1996) Cytochrome P450 superfamily: Update on new sequences, gene mapping, accession numbers, and nomenclature. Pharmacogenetics 6: 1-42
35. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ and Tsutsui M (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expresscd human P450s and human liver microsomes. Xenobiotica 26: 681-693
36. Pessayre D, Konstantinova-Mitcheva M, Descatoire V, Cobert B, Wandscheer JC, Level R, Feldmann G, Mansuy D and Benhamou JP (1981) Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration. Biochem Pharmacol 30: 559-564
37. Reidy GF, Mehta I and Murray M (1989) Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. Mol Pharmacol 35: 736-743
38. Roos PH and Mahnke A (1996) Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes. Biochem Pharmacol 52: 73-84
39. Royer I, Monsarrat B, Sonnier M, Wright M and Cresteil T (1996) Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 56: 58-65
40. Ruzicka JA and Ruenitz PC (1992) Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat. Drug Metab Dispos Biol Fate Chem 20: 770-772
41. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423
42. Skinner R, Sharkey IM, Pearson ADJ and Craft AW (1993) Ifosfamide, mesna, and nephrotoxicily in children. J Clin Oncol 11: 173-190
43. Sladek NE (1994) Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In Anticancer Drugs: Reactive Metabolism and Interactions, Powers, G. (ed), pp. 79-156. Pergamon Press: United Kingdom.
44. Sood C and O'Brien PJ (1996) 2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity [In Process Citation]. Br J Cancer 74(suppl. 27): S287-293
45. Tapner M, Liddle C, Goodwin B, George J and Farrell GC (1996) Interferon gamma down-regulates cytochrome P450 3A genes in primary cultures of well-differentiated rat hepatocytes. Hepatology 24: 367-373
46. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH and Idle JR (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47: 1157-1163
47. Walter-Sack I and Klotz U (1996) Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 31: 47-64
48. Waxman DJ (1991a) Rat hepatic P450IIA and P450IIC subfamily expression using catalytic, immunochemical, and molecular probes. Methods Enzymol 206: 249-267
49. Waxman DJ (1991b) P450-catalyzed steroid hydroxylation: assay and product identification by thin-layer chromatography. Methods Enzymol 206: 462-476
50. Waxman DJ and Walsh C (1983) Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: purification, characterization, and interactions with metyrapone and cytochrome b5. Biochemistry 22: 4846-4855
51. Waxman DJ and Azaroff L (1992) Phenobarbital induction of cytochrome P-450 gene expression. Biochem J 281: 577-592
52. Waxman DJ, Ko A and Walsh C (1983). Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. J Biol Chem 258: 11937-11947
53. Weber GF and Waxman DJ (1993) Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochem Pharmacol 45: 1685-1694
54. Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TKH, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO and Chiocca EA (1994) Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. Hum Gene Ther 5: 969-978
55. Wrighton SA and Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22: 1-21
56. Yu L and Waxman DJ (1996) Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Dispos 24: 1254-1262